[Proteic profiling SELDI-TOF and breast cancer: clinical potential applications]. 
Significant advances in early diagnosis, prognostic markers, therapeutic response and toxic effect indicators, together with the identification of new potential drug targets, have improved the survival of patients with breast cancer.  Proteomic technologies, including SELDI-TOF (surface enhanced laser desorption/ionization-time of flight) mass spectrometry, are emerging tools that may contribute to better reach these key objectives.